The study looked at the following variants of concern: alpha, beta, gamma, delta, epsilon and iota.
Researchers tested sera from a random sample of eight volunteers in three age groups: 18-55, 55-70, and 71 and older. All participants had samples available for four timepoints: four weeks after the first dose, two weeks after the second dose, 3 months after the second dose and six months after the second dose.
“These data support the durable efficacy of 93 percent seen with the Moderna COVID-19 vaccine through six months. We expect that these data and the growing body of real-world evidence will help inform health regulators’ approaches to how and when to administer additional boosting doses,” Moderna CEO Stéphane Bancel said in a news release.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
